SCHEMBL6923018

SCHEMBL6923018

Cc1cccc(-n2c(C)cc(C(=O)CN3CCCC3)c2C)c1

nearest known ligand 0.73

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 9/20 0.73
HPGD P15428 5/20 0.73
USP14 P54578 4/20 0.68
KDM4E B2RXH2 4/20 0.68
USP7 Q93009 3/20 0.68
RAB9A P51151 8/20 0.67
NPC1 O15118 6/20 0.67
USP5 P45974 2/20 0.67
NOTUM Q6P988 2/20 0.61
POLB P06746 2/20 0.60
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
TP53 P04637 2/20 0.55
MAPT P10636 2/20 0.55
ALDH1A1 P00352 4/20 0.53
LMNA P02545 2/20 0.53
GAA P10253 1/20 0.53
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6922487 0.89 SMN1; SMN2 (0.78) SMN1; SMN2HPGDUSP14KDM4EUSP7
SCHEMBL6923123 0.88 SMN1; SMN2 (0.79) SMN1; SMN2HPGDUSP14KDM4EUSP7
SCHEMBL6921808 0.88 USP14 (0.76) SMN1; SMN2HPGDUSP14KDM4EUSP7
SCHEMBL14708805 0.87 SMN1; SMN2 (0.81) SMN1; SMN2HPGDUSP14KDM4EUSP7
SCHEMBL6923422 0.87 SMN1; SMN2 (0.65) SMN1; SMN2HPGDUSP14KDM4EUSP7
SCHEMBL19501158 0.86 NOTUM (0.56) SMN1; SMN2HPGDUSP14KDM4EUSP7
SCHEMBL6922583 0.86 SMN1; SMN2 (0.97) SMN1; SMN2HPGDUSP14KDM4EUSP7
SCHEMBL16079020 0.85 SMN1; SMN2 (1.00) SMN1; SMN2HPGDUSP14KDM4EUSP7
SCHEMBL23524553 0.82 SMN1; SMN2 (0.81) SMN1; SMN2HPGDUSP14KDM4EUSP7
SCHEMBL15919335 0.81 NOTUM (0.71) SMN1; SMN2HPGDRAB9ANPC1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351568-B2 Compositions and methods for enhancing proteasome activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-07-16 US disclosed
US-9849135-B2 USP14 inhibitors for treating or preventing viral infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-12-26 US disclosed
US-9849135-B2 USP14 inhibitors for treating or preventing viral infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-12-26 US disclosed
EP-2528911-B1 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY HARVARD COLLEGE (US) 2017-10-25 EP disclosed
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity THE ASSAY DEPOT, INC. 2016-07-28 US disclosed
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity THE ASSAY DEPOT, INC. 2016-07-28 US disclosed
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2015-11-26 US disclosed
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2015-11-26 US disclosed
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-18 US disclosed
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-18 US disclosed
WO-2014116228-A1 USP14 INHIBITORS FOR TREATING OR PREVENTING VIRAL INFECTIONS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-07-31 WO disclosed
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-21 US disclosed
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-21 US disclosed
WO-2011094545-A2 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections USP14, USP1, USP13 SMN1; SMN2 1593/4885HPGD 2794/4885USP14 1/4885
US-10351568-B2 Compositions and methods for enhancing proteasome activity PSMG3, PSME3, PSMB11 SMN1; SMN2 307/4885HPGD 4170/4885USP14 12/4885
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSMB11, PSME3 SMN1; SMN2 307/4885HPGD 4149/4885USP14 6/4885
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSME3, PSMB11 SMN1; SMN2 307/4885HPGD 4170/4885USP14 12/4885
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation HSPA2, HSPBP1, HSPH1 SMN1; SMN2 544/4885HPGD 3689/4885USP14 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.